Agios Q3 2026: Mitapivat Sales Soar, SCD Decision Looms, Cash Cushion Shrinks

What happened

Agios reported Q3 2026 worldwide mitapivat net revenues of $55.4M, a fourfold increase year-over-year, driven by the U.S. launch of AQVESME for thalassemia and continued growth in PYRUKYND for PK deficiency. The company disclosed 619 cumulative prescriptions with completed start forms for AQVESME as of September 30, 2026, indicating moderate penetration of the ~6,000 adult U.S. thalassemia population but leaving questions about patient persistence and the impact of REMS monitoring requirements. The FDA set a new PDUFA goal date of February 1, 2027 for the mitapivat sickle cell disease sNDA, and Agios is in labeling discussions, suggesting regulatory engagement despite the mixed Phase 3 RISE UP results that missed key symptomatic endpoints. Agios ended the quarter with $907M in cash and marketable securities, down from $1.3B a year earlier, reflecting sustained operating cash burn as the company invests in commercial launches and pipeline programs. Management reiterated a target of non-GAAP profitability in 2028, but the path depends on continued AQVESME and PYRUKYND revenue growth and a favorable outcome in sickle cell disease, which remains a binary catalyst.

Implication

The quadrupling of mitapivat revenue to $55.4M demonstrates that the thalassemia launch is gaining commercial traction despite REMS constraints, supporting the thesis that execution risk is manageable. However, the 619 AQVESME prescriptions represent only about 10% of the addressable U.S. population, and the company has not yet disclosed persistence data or the rate of discontinuations due to mandatory liver monitoring, which could cap the market opportunity. The February 2027 PDUFA date for SCD is a critical catalyst; approval would significantly expand the total addressable market, but the FDA may require additional data or a restrictive label given the missed symptom endpoints in Phase 3. Cash reserves have declined to $907M, which still provides a multi-year runway, but investors should monitor quarterly burn rates and whether management can achieve profitability by 2028 without dilutive financing. Overall, the investment thesis remains intact but shifts toward greater confidence in commercial execution, while the SCD regulatory outcome becomes the primary driver of near-term valuation.

Thesis delta

The original thesis centered on AGIO trading at a low enterprise value with potential from AQVESME ramp and an SCD regulatory path. The Q3 2026 results confirm AQVESME is ramping and generating meaningful revenue, which de-risks the commercial execution component. However, the SCD approval remains uncertain despite a PDUFA date, and the cash balance has decreased, requiring continued financial discipline; overall, the thesis has strengthened modestly on the commercial side but still hinges on the SCD binary event.